{"filing":{"accession_number":"0001628280-26-043232","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"vtgn-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/vtgn-20260615.htm"},"events":[{"id":11101,"run_id":9732,"accession_number":"0001628280-26-043232","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses financial results for Vistagen's fiscal year ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7601,"accession_number":"0001628280-26-043232","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses financial results for Vistagen's fiscal year ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:36:05.377268+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7601,"accession_number":"0001628280-26-043232","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses financial results for Vistagen's fiscal year ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:36:05.377268+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-15"}]}